Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL

NCT06926205 is registered in ClinicalTrials.gov with GELLC (Grupo Español de Leucemia Linfocítica Crónica) as lead sponsor.

NCT NCT06926205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHOP Plus Mosunetuzumab as First Line in Patients With Richter´s Syndrome: a Phase II Study of the Spanish Group of CLL
Lead sponsor
GELLC (Grupo Español de Leucemia Linfocítica Crónica)
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2024
Completion date
May 15, 2028
Enrollment
34 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

richter syndrome